Efficacy of Stromal Vascular Fraction Versus Platelet Rich Plasma in Treatment of Androgenitic Alopecia

Launched by KASR EL AINI HOSPITAL · Aug 14, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring how effective and safe a treatment called stromal vascular fraction (SVF) is for men with androgenetic alopecia, which is a common form of hair loss. The study will compare SVF to another treatment known as platelet-rich plasma (PRP) to see which one works better for helping hair regrowth. Participants will receive one treatment on one half of their scalp and the other treatment on the other half, allowing researchers to directly compare the two methods.

To be eligible for this trial, participants must be men aged 18 and older who have a specific level of hair loss. However, those with active infections, cancer, autoimmune diseases, certain medications, or recent chemotherapy will not be able to participate. The trial is not yet recruiting participants, but once it begins, those who qualify can expect to receive both treatments in a single session. This study aims to provide valuable insights into new hair loss treatments, which could lead to better options for men dealing with this condition.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 18 years or older.
• • Hamilton score I to VI in male patients.
• Exclusion Criteria:
• • Patients with active infection, malignancy, autoimmune disease, and on current anticoagulant therapy.
• • Patient on chemotherapy during the last 5 years.
• • patients on topical or systemic treatment of AGA